Related Experiment Videos
[Sertraline and acute pancreatitis: a case-report]
André Malbergier1, Hercílio Pereira de Oliveira Júnior
1Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil. amalbergier@uol.com.br
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)
|April 2, 2004
Summary
Selective serotonin reuptake inhibitor (SSRI) sertraline may be a potential cause of acute pancreatitis. Discontinuation of sertraline led to symptom remission, suggesting a causal link in this case.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Medicine
Background:
- Acute pancreatitis is a serious condition with significant morbidity and mortality.
- Identifying risk factors for acute pancreatitis is crucial for patient management.
- Selective serotonin reuptuptake inhibitors (SSRIs) are widely prescribed antidepressants.
Observation:
- A 55-year-old female patient developed severe abdominal pain and elevated serum amylase after one month of sertraline treatment.
- Sertraline, an SSRI, was identified as a potential causative agent.
- The patient's symptoms and laboratory values improved after discontinuing sertraline.
Findings:
- The case suggests a possible causal relationship between sertraline use and the development of acute pancreatitis.
- Interruption of sertraline therapy resulted in the resolution of pancreatitis symptoms and normalization of amylase levels.
Implications:
- This association warrants consideration when evaluating patients presenting with acute pancreatitis, especially those on SSRI therapy.
- Increased awareness among clinicians regarding this potential adverse drug reaction may improve diagnostic accuracy and patient outcomes.
- Further research may be needed to establish the incidence and mechanisms of sertraline-induced pancreatitis.